Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 10, 2009, Pages 1206-1214

  Bielekova, Bibiana ^a   Richert, Nancy ^a   Howard, Thomas ^a   Packer, Amy N ^a   Blevins, Gregg ^a,b   Ohayon, Joan ^a   McFarland, Henry F ^a   Stürzebecher, Claus Steffen ^c   Martin, Roland ^a,d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c GRÜNENTHAL GMBH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autoimmunity; Blood brain barrier; Clinical trial; Multiple sclerosis; Phosphodiesterase 4; Rolipram

Indexed keywords

BETA INTERFERON; GLATIRAMER; PHOSPHODIESTERASE IV; ROLIPRAM; STEROID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; IMMUNOPHENOTYPING; INSOMNIA; MONOCYTE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE; TREATMENT FAILURE; UPREGULATION; VOMITING;

BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CELL PROLIFERATION; CONTRAST MEDIA; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; T-LYMPHOCYTES; TIME FACTORS; TREATMENT FAILURE;

EID: 72449209373     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509345903     Document Type: Article

References (38)

1. Schillace RV, Carr DW. The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions. Crit Rev Immunol 2006; 26: 113-131.
2. 2. Ekholm D, et al. Differential expression of cAMP cyclic nucleotide phosphodiesterase PDE3 and PDE4 activities in human T cell clones specific for myelin basic protein. J Immunol 1997; 159: 1520-1529. (Pubitemid 127484133)
3. 3. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007; 8: 364-372. (Pubitemid 46700993)
4. Teixeira MM, et al. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997; 18: 164-171.
5. 5. Bielekova B, et al. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164: 1117-1124. (Pubitemid 30043742)
6. Sommer N, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1: 244-248.
7. 7. Pette M, et al. Differential effects of phosphodiesterase type-4-specific inhibition on human autoreactive myelinspecific T cell clones. J Neuroimmunol 1999; 98: 147-156. (Pubitemid 29317541)
8. Folcik VA, et al. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J Neuroimmunol 1999; 97: 119-128.
9. 9. Fujimoto T, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999; 95: 35-42. (Pubitemid 29173020)
10. Genain CP, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995; 92: 3601-3605.
11. 11. Jung S, et al. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996; 68: 1-11. (Pubitemid 26279240)
12. Moore CS, et al. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(l, 1,1,3,3,3-hexafluoro-2-hydrox ypropan2-yl)-phenyl]-ethyl]-3-methylpyridine-l-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2006; 319: 63-72.
13. 13. Sommer N, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997; 79: 54-61. (Pubitemid 27454683)
14. 14. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23: 1745-1751. (Pubitemid 23236761)
15. 15. Xu H, et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest Ophthalmol Vis Sci 1999; 40: 942-950. (Pubitemid 29153260)
16. 16. Nyman U, et al. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol 1997; 108: 415-419. (Pubitemid 27242428)
17. Ross SE, et al. Suppression of TNF-β expression, inhibition of Th1 activity, and amelioration of collageninduced arthritis by rolipram. J Immunol 1997; 159: 6253-6259.
18. 18. Liang L, Beshay E, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 1998; 47: 570-575. (Pubitemid 28160447)
19. 19. Bielekova B, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-1175. (Pubitemid 30792198)
20. McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
22. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996; 135: 1-9.
23. 23. Cutter GR, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882. (Pubitemid 29219261)
24. DeCarli C, et al. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 1992; 16: 274-284.
25. Ostuni JL, et al. Correspondence of closest gradient voxels - a robust registration algorithm. J Magn Reson Imaging 1997; 7:410-415.
26. Richert ND, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006; 66(4): 551-556.
27. 27. Muraro PA, et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111: 186-194 (Pubitemid 30793205)
28. Bielekova B, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R{alpha}-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.
29. 29. Block F, et al. Rolipram reduces excitotoxic neuronal damage. Neuroreport 2001; 12: 1507-1511. (Pubitemid 32476156)
30. DeMarch Z, et al. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008; 30: 375-387.
31. Yang L, et al. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008; 211: 311-314.
32. 32. Dinter H, et al. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med 1997; 75: 95-102. (Pubitemid 27119489)
33. 33. Bielekova B, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon {beta}. Proc Natl Acad Sci USA 2004; 101: 8705-8708. (Pubitemid 38745835)
34. Frank JA, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 2002; 8(1): 24-29.
35. Stone LA, et al. The effect of interferon-β on blood-brain-barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37:611-619.
36. Stone LA, et al. Characterization of MRI response to treatment with interferon beta-lb: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997; 49: 862-869.
37. 37. Viglietta V, et al. Loss of functional suppression by CD4 + CD25 + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979. (Pubitemid 38481088)
38. 38. Astier AL, et al. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006; 116: 3252-3257. (Pubitemid 44878639)